Conjugated To Nonproteinaceous Bioaffecting Compound (e.g., Conjugated To Cancer-treating Drug, Etc.) Patents (Class 424/181.1)
-
Patent number: 10195175Abstract: The present invention relates to combination therapy with ADCs against a tumor-associated antigen, such as Trop-2, and drugs, such as microtubule inhibitors and/or PARP inhibitors. Where ADCs are used, they preferably incorporate SN-38 or another drug that induces DNA strand breaks. Preferably, the combination of ADC and PARPi or microtubule inhibitor exhibits synergistic effects against the cancer. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.Type: GrantFiled: April 6, 2017Date of Patent: February 5, 2019Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Thomas M. Cardillo
-
Patent number: 10189910Abstract: Provided herein are novel anti-DPEP3 antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.Type: GrantFiled: June 13, 2016Date of Patent: January 29, 2019Assignee: AbbVie Stemcentrx LLCInventors: Laura Saunders, Deepti Rokkam, David Liu, Mandy Boontanrart
-
Patent number: 10174094Abstract: The present invention relates to the use of a compound containing a moiety of formula (I) as a reagent for linking a compound of formula R1—H which comprises a first functional moiety of formula F1 to a second functional moiety of formula F2 wherein X, X?, Y, R1, F1 and F2 are as defined herein. The present invention also provides related processes and products. The present invention is useful for creating functional conjugate compounds, and specifically conjugates in which at least one of the constituent molecules carries a thiol group.Type: GrantFiled: February 17, 2016Date of Patent: January 8, 2019Assignee: UCL Business PlcInventors: Mark Smith, Stephen Caddick, James Baker, Vijay Chudasama
-
Patent number: 10155812Abstract: This present invention relates to compounds (e.g., TM4SF1 binding proteins, e.g., anti-TM4SF1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of SEQ ID NO: 1. In particular, the compounds of the invention are capable of being internalized into a TM4SF1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of SEQ ID NO: 1. The invention also provides methods of treating a subject having a disorder associated with pathological angiogenesis with the compounds of the invention.Type: GrantFiled: April 6, 2016Date of Patent: December 18, 2018Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Shou-Ching S. Jaminet, Harold F. Dvorak
-
Patent number: 10143756Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6-8, alternatively 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme disclosed herein to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: GrantFiled: January 29, 2018Date of Patent: December 4, 2018Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Patent number: 10130718Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.Type: GrantFiled: October 4, 2016Date of Patent: November 20, 2018Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Serengulam V. Govindan
-
Patent number: 10112999Abstract: Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.Type: GrantFiled: April 6, 2018Date of Patent: October 30, 2018Assignee: AbbVie Inc.Inventors: Edward B. Reilly, Mark Anderson
-
Patent number: 10071168Abstract: In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer ADCs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (DAR) of the antibody significantly beyond the currently available technology. This may be of particular importance when antibodies to low density antigens are used as target antibodies. The described polymer-ADCs have improved pharmacokinetics and solubility relative to traditional ADCs. The linker between agent and the polymer can be tailored to provide release of toxin at the desired site and under the desired conditions within the tumor. An additional feature of the polymer-ADCs of the current disclosure is that a purification moiety can be attached to the polymer backbone to provide ease of purification of the polymer-ADCs.Type: GrantFiled: July 31, 2015Date of Patent: September 11, 2018Assignee: Serina Therapeutics, Inc.Inventors: Randall W Moreadith, Michael D Bentley, Zhihao Fang, Tacey Viegas
-
Patent number: 10034950Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: GrantFiled: November 14, 2017Date of Patent: July 31, 2018Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Patent number: 9951133Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.Type: GrantFiled: June 2, 2016Date of Patent: April 24, 2018Assignee: GENENTECH, INC.Inventors: Shang-Fan Yu, Wei-Ching Liang, Yan Wu, Steven Leong, Andrew Polson
-
Patent number: 9931417Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6-8, alternatively 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme disclosed herein to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: GrantFiled: June 29, 2016Date of Patent: April 3, 2018Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Patent number: 9855344Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: GrantFiled: February 24, 2017Date of Patent: January 2, 2018Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Patent number: 9797907Abstract: Described herein are compositions and methods of use of anti-Trop-2 antibodies or antigen-binding fragment thereof to isolate, enrich, detect, diagnose and/or characterize circulating tumor cells (CTCs) from patients with a Trop-2 positive cancer. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. The compositions and methods are of use to detect, diagnose and/or treat metastatic Trop-2+ cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, rectum, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer.Type: GrantFiled: April 22, 2016Date of Patent: October 24, 2017Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang
-
Patent number: 9775915Abstract: Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group -L1-(A-L2)a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment.Type: GrantFiled: November 26, 2013Date of Patent: October 3, 2017Assignee: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Daniel J. Smaltz, Andreas Schumacher
-
Patent number: 9777071Abstract: Provided herein are novel anti-DPEP3 antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.Type: GrantFiled: October 21, 2016Date of Patent: October 3, 2017Assignee: ABBVIE STEMCENTRX LLCInventors: Laura Saunders, Deepti Rokkam, David Liu, Mandy Boontanrart
-
Patent number: 9738602Abstract: A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody.Type: GrantFiled: December 18, 2015Date of Patent: August 22, 2017Assignee: Wyeth LLCInventors: George Anello Chiarello, Ayman Sahli
-
Patent number: 9724427Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.Type: GrantFiled: May 20, 2013Date of Patent: August 8, 2017Assignee: Genentech, Inc.Inventors: Chie Sakanaka, Peter Chang
-
Patent number: 9629926Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: GrantFiled: May 23, 2016Date of Patent: April 25, 2017Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Patent number: 9598490Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: GrantFiled: December 15, 2015Date of Patent: March 21, 2017Assignee: ImmunoGen, Inc.Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
-
Patent number: 9499631Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.Type: GrantFiled: October 16, 2015Date of Patent: November 22, 2016Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Patent number: 9481732Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.Type: GrantFiled: December 1, 2015Date of Patent: November 1, 2016Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Patent number: 9475884Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.Type: GrantFiled: March 26, 2015Date of Patent: October 25, 2016Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Patent number: 9458242Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.Type: GrantFiled: March 12, 2015Date of Patent: October 4, 2016Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Patent number: 9375489Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: GrantFiled: July 1, 2015Date of Patent: June 28, 2016Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Patent number: 9351986Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: GrantFiled: March 7, 2014Date of Patent: May 31, 2016Assignee: WYETH HOLDINGS LLCInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
-
Patent number: 9278118Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: GrantFiled: October 20, 2014Date of Patent: March 8, 2016Assignees: BIOREC S.A., CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Silvio Ernesto Perea Rodriguez, Yasser Perera Negrin, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Patent number: 9242012Abstract: Methods of killing prostate-specific membrane antigen (PSMA)-expressing, taxane-resistant cancer cells are provided. In particular, PSMA-expressing, taxane-resistant cancer cells are contacted with an antibody-drug conjugate (ADC) that comprises an antibody or antigen-binding fragment thereof that specifically binds to PSMA conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine.Type: GrantFiled: February 17, 2011Date of Patent: January 26, 2016Assignee: PSMA Development Company, LLCInventors: Dangshe Ma, William C. Olson, Stephen Morris, Robert J. Israel
-
Patent number: 9239324Abstract: The present invention provides compositions and methods for preparing protein drug conjugate and its application to stem cell therapy and treating cancer cells. The composition is an antibody-binding-therapeutic drug conjugate that binds antibodies targeted to cancer or stem cells. The method of using the composition includes the steps of combining an antibody that targets the cancer cells or stem cells with a sample for a time sufficient to allow said antibody to bind the targeted cells present in said sample and adding the antibody-binding-drug conjugate for a time sufficient to allow binding to the antibody bound to the targeted cells. The presence of the drug reduces the number of or eliminates the targeted cancer cells or stem cells. A similar method is disclosed for selecting antibodies that may be effective antibody drug conjugates.Type: GrantFiled: December 6, 2013Date of Patent: January 19, 2016Inventors: Gang Chen, Zhenwei Miao
-
Patent number: 9226946Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: GrantFiled: September 19, 2014Date of Patent: January 5, 2016Assignees: BIOREC S.A., CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Silvio Ernesto Perea Rodríguez, Yasser Perera Negrín, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Patent number: 9198978Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: GrantFiled: March 2, 2015Date of Patent: December 1, 2015Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
-
Patent number: 9175089Abstract: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.Type: GrantFiled: March 29, 2013Date of Patent: November 3, 2015Assignee: Genentech, Inc.Inventors: Jo-Anne Hongo, Weiguang Mao, Paul Polakis, Andrew Polson, Rajesh Vij, Yan Wu, Wei-Ching Liang
-
Patent number: 9168256Abstract: There is disclosed stable pharmaceutical compositions containing pharmaceutically acceptable salts of aminopterin surface deposited onto solid excipients. The stable pharmaceutical compositions are hermetically sealed from the atmosphere. The formation of degradation products of aminopterin is reduced or eliminated.Type: GrantFiled: October 30, 2007Date of Patent: October 27, 2015Assignee: Aminopterin LLCInventors: Absar Faruqui, John A. Zebala, Barton A. Kamen
-
Patent number: 9107960Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: GrantFiled: April 17, 2014Date of Patent: August 18, 2015Assignee: Immunimedics, Inc.Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Patent number: 9061995Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: GrantFiled: November 14, 2013Date of Patent: June 23, 2015Assignee: ImmunoGen, Inc.Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Patent number: 9034330Abstract: A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex.Type: GrantFiled: May 11, 2007Date of Patent: May 19, 2015Assignee: Georgetown UniversityInventors: Esther H. Chang, Kathleen F. Pirollo
-
Publication number: 20150132308Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.Type: ApplicationFiled: November 10, 2014Publication date: May 14, 2015Inventors: Stephen D. Gillies, David Azria, Christel Larbouret, André Pelegrin
-
Patent number: 9028833Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.Type: GrantFiled: July 23, 2013Date of Patent: May 12, 2015Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20150125386Abstract: The present invention concerns compositions and methods of use of a humanized Class III anti-CEA antibody, comprising the heavy and light amino acid sequences SEQ ID NO:1 and SEQ ID NO:2. The antibody is effective to treat CEACAM5-expressing tumors, either alone or in combination with one or more therapeutic agents. Drug conjugated Class III anti-CEA antibodies, such as SN-38 or P2PDox immunoconjugates, are particularly efficacious. Surprisingly, the antibody-drug conjugates (ADCs) exhibit high anti-cancer efficacy, while exhibiting low levels of systemic toxicity that are readily treated with standard amelioration techniques. Antibodies and/or immunoconjugates comprising the amino acid sequences SEQ ID NO:1 and SEQ ID NO:2 are surprisingly efficacious for therapy of solid tumors, even when the tumor has proven resistant to standard anti-cancer therapies.Type: ApplicationFiled: October 16, 2014Publication date: May 7, 2015Inventors: Hans J. Hansen, David M. Goldenberg
-
Patent number: 9023356Abstract: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.Type: GrantFiled: March 14, 2008Date of Patent: May 5, 2015Assignees: Ludwig Institute for Cancer Research Ltd, The Regents of the University of CaliforniaInventors: Terrance Grant Johns, Webster Cavenee, Frank Furnari, Andrew Scott
-
Publication number: 20150118316Abstract: Disclosed is a composition immunologically targeted to Alzheimer's disease (AD), the composition containing amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an amyloid-beta antigen associated with AD. The invention also includes a medication manufactured with the targeted nanoceria particles and methods of treatment by administering the targeted nanoceria particles to patients in need thereof.Type: ApplicationFiled: November 3, 2014Publication date: April 30, 2015Applicants: University of Central Florida Research Foundation, Inc., University of L'AquilaInventors: Sudipta Seal, Soumen Das, Annamaria Cimini, Barbara D'Angelo
-
Publication number: 20150110816Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.Type: ApplicationFiled: June 4, 2014Publication date: April 23, 2015Applicants: GENENTECH, INC., IMMUNOGEN INC.Inventors: Walter BLATTLER, Ravi V.J. CHARI, Mark SLIWKOWSKI, Sharon ERICKSON, Ralph SCHWALL
-
Publication number: 20150110817Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group.Type: ApplicationFiled: May 13, 2013Publication date: April 23, 2015Inventors: Hanne Therese Bonge-Hansen, Olav Benjamin Ryan
-
Publication number: 20150104469Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.Type: ApplicationFiled: March 14, 2013Publication date: April 16, 2015Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere
-
Patent number: 8999334Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.Type: GrantFiled: March 26, 2013Date of Patent: April 7, 2015Assignee: Viventia Bio Inc.Inventors: Francina C. Chahal, Jeannick Cizeau
-
Patent number: 8999344Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: GrantFiled: June 3, 2014Date of Patent: April 7, 2015Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
-
Publication number: 20150071950Abstract: Disclosed is a conjugate in which a c-Met targeting compound and a bioactive material are chemically conjugated with each other, and methods of use thereof.Type: ApplicationFiled: September 12, 2014Publication date: March 12, 2015Inventors: Su Young Chae, Sunghyun Kim, Eun Ko, Yun Ju Jeong, Jae Hyun Choi
-
Publication number: 20150071949Abstract: New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the ?-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.Type: ApplicationFiled: August 14, 2014Publication date: March 12, 2015Inventors: Ravi V.J. Chari, Wayne C. Widdison
-
Patent number: 8968742Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.Type: GrantFiled: August 23, 2013Date of Patent: March 3, 2015Assignee: Agensys, Inc.Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
-
Patent number: 8968741Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.Type: GrantFiled: February 6, 2013Date of Patent: March 3, 2015Assignee: Genentech, Inc.Inventors: Allen J. Ebens, Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
-
Patent number: RE47103Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.Type: GrantFiled: March 2, 2017Date of Patent: October 30, 2018Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia